<?xml version='1.0' encoding='utf-8'?>
<document id="27816979"><sentence text="Evaluation of the Potential Pharmacokinetic Interaction between Atomoxetine and Fluvoxamine in Healthy Volunteers."><entity charOffset="64-75" id="DDI-PubMed.27816979.s1.e0" text="Atomoxetine" /><entity charOffset="80-91" id="DDI-PubMed.27816979.s1.e1" text="Fluvoxamine" /><pair ddi="false" e1="DDI-PubMed.27816979.s1.e0" e2="DDI-PubMed.27816979.s1.e0" /><pair ddi="false" e1="DDI-PubMed.27816979.s1.e0" e2="DDI-PubMed.27816979.s1.e1" /></sentence><sentence text="Attention deficit hyperactivity disorder (ADHD) is frequently associated with other psychiatric pathologies" /><sentence text=" Therefore, the present study investigated a possible pharmacokinetic interaction between atomoxetine (ATX), a treatment option for ADHD, and an antidepressant, namely, fluvoxamine (FVX)"><entity charOffset="90-101" id="DDI-PubMed.27816979.s3.e0" text="atomoxetine" /><entity charOffset="169-180" id="DDI-PubMed.27816979.s3.e1" text="fluvoxamine" /><entity charOffset="182-185" id="DDI-PubMed.27816979.s3.e2" text="FVX" /><pair ddi="false" e1="DDI-PubMed.27816979.s3.e0" e2="DDI-PubMed.27816979.s3.e0" /><pair ddi="false" e1="DDI-PubMed.27816979.s3.e0" e2="DDI-PubMed.27816979.s3.e1" /><pair ddi="false" e1="DDI-PubMed.27816979.s3.e0" e2="DDI-PubMed.27816979.s3.e2" /><pair ddi="false" e1="DDI-PubMed.27816979.s3.e1" e2="DDI-PubMed.27816979.s3.e1" /><pair ddi="false" e1="DDI-PubMed.27816979.s3.e1" e2="DDI-PubMed.27816979.s3.e2" /></sentence><sentence text="" /><sentence text="Designed as an open-label, non-randomized clinical trial, the study included 2 periods" /><sentence text=" In period 1 (reference), each subject received ATX 25 mg (single-dose), whereas in period 2 (test), all subjects were given a combination of ATX 25 mg + FVX 100 mg, following a 6-day pretreatment regimen with the enzymatic inhibitor"><entity charOffset="154-156" id="DDI-PubMed.27816979.s6.e0" text="FVX" /></sentence><sentence text=" Non-compartmental methods were employed to determine the pharmacokinetic parameters of ATX and its main active metabolite (glucuronidated form), 4-hydroxyatomoxetine-O-glucuronide" /><sentence text="" /><sentence text="The results revealed significant differences between the study periods for Cmax, AUC0-t and AUC0-∞ values corresponding to ATX and its metabolite" /><sentence text=" Small, but statistically significant increases in AUC values were reported for both parent drug (1,583" /><sentence text="05 ± 1,040" /><sentence text="29 vs" /><sentence text=" 2,111" /><sentence text="55 ± 1,411" /><sentence text="59 ng*h/ml) and 4-hydroxyatomoxetine-O-glucuronide (5,754"><entity charOffset="16-50" id="DDI-PubMed.27816979.s15.e0" text="4-hydroxyatomoxetine-O-glucuronide" /></sentence><sentence text="71 ± 1,235" /><sentence text="5 vs" /><sentence text=" 6,293" /><sentence text="17 ± 1,219" /><sentence text="34 ng*h/ml) after combined treatment of ATX and the enzymatic inhibitor" /><sentence text="" /><sentence text="FVX had a modest effect on the pharmacokinetics of ATX and 4-hydroxyatomoxetine-O-glucuronide"><entity charOffset="59-93" id="DDI-PubMed.27816979.s22.e0" text="4-hydroxyatomoxetine-O-glucuronide" /><entity charOffset="0-33" id="DDI-PubMed.27816979.s22.e1" text="FVX" /><pair ddi="false" e1="DDI-PubMed.27816979.s22.e1" e2="DDI-PubMed.27816979.s22.e1" /><pair ddi="false" e1="DDI-PubMed.27816979.s22.e1" e2="DDI-PubMed.27816979.s22.e0" /></sentence><sentence text=" The presence or absence of any clinical consequences associated with this pharmacokinetic drug-drug interaction needs to be established in future studies" /><sentence text="" /></document>